Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
It represents a significant advancement in obesity treatment, with millions worldwide experiencing meaningful weight loss
Other information Content details Last updated on 02 Aug 2026 | 01:03 AM (IST) Manufacturer details Name: A)Apco Pharma Ltd
Retatrutide has been researched as a triple agonist targeting GLP-1, GIP, and glucagon receptors
Unlike short-term diets, tirzepatide treatment often extends beyond initial weight loss phases, supporting sustained health improvements that require ongoing medication management
The additional GIP receptor activity is thought to further amplify insulin release and may play a role in fat metabolism
US$ 20.12
US$ 22.63
US$ 24.13
US$ 26.98
